Arcus Biosciences’ (RCUS) Quiet Period To End Tomorrow
Arcus Biosciences’ (NYSE:RCUS) quiet period is set to expire on Tuesday, April 24th. Arcus Biosciences had issued 8,000,000 shares in its public offering on March 15th. The total size of the offering was $120,000,000 based on an initial share price of $15.00. During the company’s quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
Several research analysts have recently weighed in on the company. Citigroup began coverage on Arcus Biosciences in a report on Monday, April 9th. They set a “buy” rating and a $18.00 target price on the stock. Leerink Swann began coverage on shares of Arcus Biosciences in a research report on Monday, April 9th. They set an “outperform” rating and a $21.00 price target on the stock. Finally, Goldman Sachs began coverage on shares of Arcus Biosciences in a research report on Monday, April 9th. They set a “neutral” rating and a $18.00 price target on the stock.
RCUS stock opened at $16.30 on Monday. Arcus Biosciences has a one year low of $13.26 and a one year high of $22.10.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.